The Blood Connection Inc

What it reported doing in 2024

Blood donor program: allogeneic whole blood donor program: affords free opportunity for patrons to participate in community service in the form of voluntary whole blood donations. For donors - early detection & treatment opportunity for high blood pressure, anemia, abnormal pulse rate and other illnesses found during blood donor screening. Autologous blood program: affords free opportunity for patients to provide their own blood in advance of medical treatment. Reduction in demand on community blood supply, reduced risk of transfusion transmitted disease. Directed blood donor program: affords opportunity for patients to designate donors of the blood for the patients transfusions. Automated collection apheresis (platelet, plasma & rbc) donor program: affords free opportunity for patrons to participate in community service in the form of voluntary, automated donations. Therapeutic service program: provides free therapeutic phlebotomy for patients with blood disorders such a polycythemia and hemochromatosis. Cellular program: hematopoietic progenitor cell processing services: provides cellular therapy services including processing, cryopreservation, storage, infusion preparations for immunotherapy, and transplant for both autologous and matched related transplants for multiple myeloma, nhl and hodgkinis lymphoma. Provides transplant product preparation and shipment preparation to an outside facility upon request. The cryogenic storage services are provided free of charge for the first year. Goals: process 100% of requests for processing and infusions of hematopoietic progenitor cells and donor lymphocytes, offer services 24/7, provide same day turnaround for cd34+ flow cytometry analysis, and produce a product proven to be capable of engraftment. Cellular therapy collection services: provides cellular collection services for two healthcare providers. One, a biotechnology company (dendreon) applies its expertise in antigen identification, engineering and cell processing to produce an active cellular immunotherapy product called provenge (sipuleucel-t). Provenge is indicated for treatment of asymptomatic or minimally symptomatic metastatic castrate resistant prostate cancer. The blood connection collects mononuclear cells from prostate cancer patients deemed suitable by their physician and scheduled by dendreon. Post collection, the collected product is shipped to dendreon for further testing and processing; the final product is later transfused back to the patient at their transfusion center. The other provider is a cancer treatment institute affiliated with a local hospital system. The blood connection collects circulating bone marrow cells from patients in the remission phase of cellular cancers such as leukemia, lymphoma, and myeloma. Those collections, rich in hematopoietic progenitor cells, are then processed as described above.

Financial Efficiency

• Mission deployment rate: 89.1%; rating input score 89
• Program expense ratio: 94.2%; rating input score 94
• Fundraising efficiency: Limited

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 68th percentile among comparable filings
• Pay-setting controls: 6 of 6 controls in place; rating input score 100
  • Compensation committee: Pass
  • Independent consultant: Pass
  • Other Form 990s reviewed: Pass
  • Written employment contract: Pass
  • Compensation survey or study: Pass
  • Board or committee approval: Pass
• Foreign activity oversight: Limited
• Grant itemization coverage: Limited
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 100%; rating input score 100; 77th percentile among comparable filings
• Governance controls: 9 of 9 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: 5.6%; rating input score 59; 59th percentile among comparable filings
• Total-asset coverage ratio: 0.76; rating input score 30; 30th percentile among comparable filings
• Liabilities to assets ratio: 0.32; rating input score 54; 54th percentile among comparable filings
• Officer compensation ratio: 3.1%; rating input score 37; 37th percentile among comparable filings

Growth

• Program expense growth: 14.5% per year; rating input score 100; 86th percentile among comparable filings
• Revenue growth: 12.4% per year; rating input score 100; 84th percentile among comparable filings
• Asset growth: 8.5% per year; rating input score 100; 62nd percentile among comparable filings